RT Journal Article
SR Electronic
T1 Long-term Outcomes of Peripheral Artery Disease In Veterans: Analysis of the PEripheral ARtery Disease Long-term Survival Study (PEARLS)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.20.24312328
DO 10.1101/2024.08.20.24312328
A1 Girotra, Saket
A1 Li, Qiang
A1 Vaughan-Sarrazin, Mary
A1 Lund, Brian C.
A1 Al-Garadi, Mohammad
A1 Beckman, Joshua A.
A1 Nathani, Rohit
A1 Hoffman, Richard M.
A1 Chan, Paul S.
A1 Banerjee, Subhash
A1 Tsai, Shirling
A1 Kumbhani, Dharam J.
A1 Minniefield-Young, Nicole
A1 Smolderen, Kim G.
A1 Arya, Shipra
A1 Nguyen, Cathy
A1 Matheny, Michael E.
A1 Gobbel, Glenn T.
YR 2024
UL http://medrxiv.org/content/early/2024/08/21/2024.08.20.24312328.abstract
AB Background Contemporary research in peripheral artery disease (PAD) remains limited due to lack of a national registry and low accuracy of diagnosis codes to identify PAD patients in electronic health records.Methods & Results Leveraging a novel natural language processing (NLP) system that identifies PAD with high accuracy using ankle brachial index (ABI) and toe-brachial index (TBI) values, we created a registry of 103,748 patients with new onset PAD patients in the Veterans Health Administration (VHA). Study endpoints include mortality, cardiovascular (hospitalization for acute myocardial infarction or stroke) and limb events (hospitalization for critical limb ischemia or major amputation) and were identified using VA and non-VA encounters. The mean age was 70.6 years; 97.3% were males, and 18.5% self-identified as Black race. The mean ABI value was 0.78 (SD: 0.26) and the mean TBI value was 0.51 (SD: 0.19). Nearly one-third (32.4%) patients were currently smoking and 35.4% formerly smoked. Prevalence of hypertension (86.6%), heart failure (22.7%), diabetes (54.8%), renal failure (23.6%), and chronic obstructive pulmonary disease (35.4%) was high. At 1-year, 9.4% of patients had died. The 1-year incidence of cardiovascular events was 5.6 per 100 patient-years and limb events was 4.5 per 100 patient-years.Conclusions We have successfully launched a registry of >100,000 patients with a new diagnosis of PAD in the VHA, the largest integrated health system in the U.S. The ncidence of death and clinical events in our cohort is high. Ongoing studies will yield important insights regarding improving care and outcomes in this high-risk group.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study is funded by the National Heart, Lung and Blood Institute (NHLBI, R01HL166305 and R56HL158803; PI: Girotra; Co-I: Vaughan-Sarrazin, Lund, Al-Garadi, Beckman, Hoffman, Tsai, Smolderen, Arya, Matheny, Gobbel). Dr. Lund receives funding from the VA Office of Research and Development and the VA Office of Rural Health. Dr. Chan and Dr. Girotra also receive receive funding from the NHLBI (R01HL160734) and the American Heart Association. This material is the result of work supported with resources and the use of facilities at the Iowa City, Nashville and North Texas Veterans Affairs. None of the funders had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation for publication. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the Institutional Review Board (IRB) and Research & Development Committees at Dallas, Iowa City and Tennessee Valley Health System VA centers as well as the IRBs at University of Texas Southwestern Medical Center and University of Iowa.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableDue to the proprietary nature of the data used in the study, data cannot be made available